Inclusion Criteria:  Histologically confirmed diagnosis of primary bone tumor (osteosarcoma)  Age from 24 to 40 years  Operable process, possibility of performing resection R0-R1  ECOG performance score 0 or 1  Normal renal function (estimated creatinine clearance more than 60 ml / min)  Normal liver function (AST, ALT - no more than 3 norms)  Left ventricular ejection fraction> 55%  Adequate marrow function (hemoglobin level more than 9 g / dL, neutrophil count more than 1.5 thousand / μl, platelet number more than 100 thousand / μl)  Signed informed consent  Exclusion Criteria:  Children, women during pregnancy, childbirth, women during breastfeeding  Persons with mental disorders  The presence of an active viral infection with HIV, viral hepatitis B and C  Inoperable tumor  Morphologically confirmed diagnosis of GIST, Kaposi's sarcoma, alveolar or clear cell sarcoma, chondrosarcoma, chordoma, giant cell tumor, paraosal osteosarcoma, Ewing's sarcoma / PNET, rhabdomyosarcoma, G1 osteosarcoma  The presence of a second malignant neoplasm within the last 5 years before enrollment, other than cured basal cell or squamous cell carcinoma or cervical cancer in situ, prostate cancer  Clinically significant cardiovascular or cerebrovascular diseases within the last 6 months (acute myocardial infarction, unstable angina pectoris, significant ventricular arrhythmias, severe heart failure (NYHA class IV), stroke or uncontrolled arterial hypertension)  Renal failure (serum creatinine level more than 150 μmol / L), except for cases caused by lymphoid infiltration of the kidneys, and tumor disintegration syndrome  Hepatic failure (except for cases caused by leukemic / lymphoid organ infiltration), acute hepatitis (serum bilirubin level more than 2 norms, ALT and AST activity more than 4 norms, prothrombin index less than 50%)  Decompensated diabetes mellitus (blood serum glucose above 15 mmol / L)  Sepsis (septicopyemic foci, hemodynamic instability; ineffective antimicrobial therapy) or acute infectious diseases  Brain metastases  Life-threatening conditions (bleeding, tumor decay, etc.)  Hypersensitivity to the active substance of the investigational drugs or any of the auxiliary components or their intolerance  Surgical interventions less than 21 days before starting therapy